Register now to learn about a new option for relapsed or refractory follicular lymphoma

General Discussions

Potential for Folate Deficiency with Olaparib

By Lisa Schulmeister, MN, RN, FAAN
Clinicians at Rush University Medical Center in Chicago, Illinois recently reported a case of severe folate deficiency in a woman taking olaparib (Lynparza) for relapsed ovarian cancer. Their observation of a nearly undetectable serum folate level without a plausible explanation led them to review other olaparib-treated patients with severe folate deficiency.

They found anemia in 6 out of 7 of these patients (mean time 39 days from initiation of olaparib to hemoglobin nadir), which in some cases necessitated blood transfusion, dose reduction, and drug discontinuation. Results were reported in an abstract published in the 2018 ASCO annual meeting supplement of the Journal of Clinical Oncology.

Patients found to be folate deficient were started on oral folic acid supplementation of 1 mg daily and had their hemoglobin levels monitored.

The researchers concluded that assessment for folate deficiency in patients taking olaparib is warranted, and further study is needed to identify interactions among PARP-inhibition, the folate pathway, and BRCA mutations in ovarian and other cancers.

Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.